These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 38936102)

  • 1. Prognostic value of the international association for the study of lung cancer grading system and its association with the tumor microenvironment in stage I EGFR-muted lung adenocarcinoma.
    Kubota S; Taki T; Miyoshi T; Tane K; Samejima J; Aokage K; Wakabayashi M; Nomura K; Nagamine M; Kojima M; Sakashita S; Sakamoto N; Tsuboi M; Ishii G
    Eur J Cancer; 2024 Aug; 207():114184. PubMed ID: 38936102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutation.
    Kitagawa S; Zenke Y; Taki T; Aokage K; Sakai T; Shibata Y; Izumi H; Nosaki K; Umemura S; Matsumoto S; Yoh K; Sakamoto N; Sakashita S; Kojima M; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2024 Feb; 188():107453. PubMed ID: 38160515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma.
    Sakai T; Aokage K; Neri S; Nakamura H; Nomura S; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Iyoda A; Tsuboi M; Ishii G
    Lung Cancer; 2018 Dec; 126():64-71. PubMed ID: 30527194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
    Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
    Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abundant tumor promoting stromal cells in lung adenocarcinoma with hypoxic regions.
    Nakamura H; Ichikawa T; Nakasone S; Miyoshi T; Sugano M; Kojima M; Fujii S; Ochiai A; Kuwata T; Aokage K; Suzuki K; Tsuboi M; Ishii G
    Lung Cancer; 2018 Jan; 115():56-63. PubMed ID: 29290263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
    Saruwatari K; Ikemura S; Sekihara K; Kuwata T; Fujii S; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ochiai A; Kohrogi H; Tsuboi M; Goto K; Ishii G
    Lung Cancer; 2016 Jan; 91():7-14. PubMed ID: 26711928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR mutation impacts recurrence in high-risk early-stage lung adenocarcinoma in the IASLC grading system.
    Nomura K; Aokage K; Kaminuma Y; Nakai T; Wakabayashi M; Ikeno T; Koike Y; Taki T; Miyoshi T; Tane K; Samejima J; Ishii G; Tsuboi M
    Int J Clin Oncol; 2024 Mar; 29(3):248-257. PubMed ID: 38319510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma.
    Ito M; Miyata Y; Kushitani K; Ueda D; Takeshima Y; Okada M
    BMC Cancer; 2023 Mar; 23(1):248. PubMed ID: 36918771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between the number of viable tumor cells and immune cells in the tumor microenvironment in non-small cell lung cancer after induction therapy.
    Hoshino H; Aokage K; Miyoshi T; Tane K; Kojima M; Sugano M; Kuwata T; Ochiai A; Suzuki K; Tsuboi M; Ishii G
    Pathol Int; 2021 Aug; 71(8):512-520. PubMed ID: 34115921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Insights Into the International Association for the Study of Lung Cancer Grading System for Lung Adenocarcinoma.
    Tan KS; Reiner A; Emoto K; Eguchi T; Takahashi Y; Aly RG; Rekhtman N; Adusumilli PS; Travis WD
    Mod Pathol; 2024 Jul; 37(7):100520. PubMed ID: 38777035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma.
    Suzuki J; Aokage K; Neri S; Sakai T; Hashimoto H; Su Y; Yamazaki S; Nakamura H; Tane K; Miyoshi T; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Tsuboi M; Ishii G
    Lung Cancer; 2021 Mar; 153():1-10. PubMed ID: 33429158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
    Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A
    Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-grade tumor classified by new system is a prognostic predictor in resected lung adenocarcinoma.
    Yoshida C; Yokomise H; Ibuki E; Go T; Haba R; Kadota K
    Gen Thorac Cardiovasc Surg; 2022 May; 70(5):455-462. PubMed ID: 35050467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different prognostic role of EGFR mutation according to the IASLC histological grade in patients with resected early-stage lung adenocarcinoma.
    Hong TH; Hwang S; Choi YL; Lee G; Park S; Ahn MJ; Lee Y; Jeon YJ; Lee J; Shin S; Park SY; Cho JH; Choi YS; Kim J; Shim YM; Cho J; Kim HK
    Histopathology; 2023 Aug; 83(2):168-177. PubMed ID: 36849852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational Profile and New IASLC/ATS/ERS Classification Provide Additional Prognostic Information about Lung Adenocarcinoma: A Study of 125 Patients from Brazil.
    de Melo AC; Karen de Sá V; Sternberg C; Olivieri ER; Werneck da Cunha I; Fabro AT; Carraro DM; de Barros e Silva MJ; Pimenta Inada HK; de Mello ES; Soares FA; Takagaki T; Ferreira CG; Capelozzi VL
    Oncology; 2015; 89(3):175-86. PubMed ID: 25833149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Impact of Genomic and Pathway Alterations in Stage I EGFR-Mutant Lung Adenocarcinoma.
    Lee JS; Kim EK; Kim KA; Shim HS
    Cancer Res Treat; 2024 Jan; 56(1):104-114. PubMed ID: 37499696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological differences between EGFR mutated and EGFR wild-type lung adenocarcinoma with papillary predominant pattern.
    Goto E; Taki T; Nomura K; Miyakami Y; Miyoshi T; Tane K; Samejima J; Aokage K; Nagamine M; Sakashita S; Sakamoto N; Kojima M; Suzuki K; Tsuboi M; Ishii G
    Lung Cancer; 2024 Jun; 192():107830. PubMed ID: 38805901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of extensive lymph node dissection in the new grading system for lung adenocarcinoma.
    Liu C; Wang LC; Chang JF; Lin KH; Yeh YC; Hsu PK; Huang CS; Hsieh CC; Hsu HS
    Eur J Surg Oncol; 2024 Oct; 50(10):108540. PubMed ID: 39178686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrating IASLC grading and radiomics for predicting postoperative outcomes in stage IA invasive lung adenocarcinoma.
    Chen Y; Wu J; You J; Gao M; Lu S; Sun C; Shu Y; Wang X
    Med Phys; 2024 Sep; 51(9):6513-6524. PubMed ID: 38781536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
    Chao L; Yi-Sheng H; Yu C; Li-Xu Y; Xin-Lan L; Dong-Lan L; Jie C; Yi-Lon W; Hui LY
    Lung Cancer; 2014 Nov; 86(2):164-9. PubMed ID: 25236981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.